Richard S. Lindahl - Mar 13, 2024 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
EVP, Chief Financial Officer
Signature
/s/ Jennifer Lynne Fox, Attorney-in-fact
Stock symbol
EBS
Transactions as of
Mar 13, 2024
Transactions value $
$0
Form type
4
Date filed
3/15/2024, 05:15 PM
Previous filing
Mar 4, 2024
Next filing
Jun 11, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EBS Employee Stock Options (Right to Buy) Award $0 +125K +69.08% $0.00 306K Mar 13, 2024 Common Stock 125K $2.33 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.